The paper “Cost‑effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden”, co-authored by Quantify’s Amanda Hansson-Hedblom, Fredrik Borgström, and Linda Karlsson, has been published in Cost Effectiveness and Resource Allocation. See the full article here.